Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?

By Zacks Equity Research | July 23, 2025, 9:57 AM

Vertex Pharmaceuticals, Inc

Zai Lab Limited ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Vertex Pharmaceuticals, Inc

Zai Lab Limited ADR

Latest News

3 hours	Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12 VRTX Business Wire
Dec-19	Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? VRTX Motley Fool
Dec-17	2 Reasons to Watch VRTX and 1 to Stay Cautious VRTX StockStory
Dec-17	Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note VRTX Zacks
Dec-15	12 Days of Investing: My Top 12 Stocks to Buy Before 2026 VRTX Motley Fool
Dec-12	2 Healthcare Stocks to Buy Ahead of the New Year VRTX Motley Fool
Dec-12	Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know VRTX Zacks
Dec-12	3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term VRTX Motley Fool
Dec-11	Earnings update: Zoom, Virgin Galactic, Nvidia, Warner Bros Discovery and more VRTX CFO.com
Dec-09	Stock Market Today: Dow Up Ahead Of Fed Meeting; Nvidia Falls Despite Trump Comments (Live Coverage) VRTX Investor's Business Daily
Dec-08	Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term VRTX Zacks
Dec-08	Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis ZLAB Business Wire
Dec-07	Zai Lab Announces Updates to Chinas National Reimbursement Drug List ZLAB Business Wire
Dec-06	Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? VRTX Motley Fool
Dec-06	Vertex Presents New Data on CASGEVY, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions VRTX Business Wire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.